117. Pharmacoeconomics. 2018 Mar;36(3):383-384. doi: 10.1007/s40273-018-0621-x.Optimality, Future and Terminal Costs: Comment on "Adjuvant Trastuzumab Therapyfor Early HER2-Positive Breast Cancer in Iran".Gershon N(1), Berchenko Y(2).Author information: (1)Department of Industrial Engineering and Management, Ben-Gurion University of the Negev, Beer-Sheva, 84105, Israel.(2)Department of Industrial Engineering and Management, Ben-Gurion University of the Negev, Beer-Sheva, 84105, Israel. berchenk@bgu.ac.il.DOI: 10.1007/s40273-018-0621-x PMID: 29441474 